Back |
home / stock / nktx / nktx message board
Subject | By | Source | When |
---|---|---|---|
Let's go $NKTX ..... | crudeoil24 | investorshub | 04/25/2022 4:04:32 PM |
PR https://www.globenewswire.com/news-release/2022/04/25/2427988/0/en/Nkarta-Ann | jondoeuk | investorshub | 04/25/2022 4:04:07 PM |
PT > 81.00 > Cowen. | crudeoil24 | investorshub | 04/25/2022 3:29:50 PM |
And you too, Sir, did you grab any | Just-Keep-Trying | investorshub | 04/25/2022 3:23:53 PM |
Did you grab any of this today?????????? Or, | Just-Keep-Trying | investorshub | 04/25/2022 3:22:58 PM |
Ongoing shelf placement will drain any gains > | crudeoil24 | investorshub | 04/25/2022 3:06:32 PM |
Trading float is 19M | crudeoil24 | investorshub | 04/25/2022 3:00:27 PM |
Shares of Nkarta Inc. ($NKTX) skyrocketed 92.8% in | crudeoil24 | investorshub | 04/25/2022 2:50:42 PM |
$NKTX @ 15.15 up 96 % after positive CC. | crudeoil24 | investorshub | 04/25/2022 2:48:47 PM |
previous close 7.77 almost +$10 WOW | TheFinalCD | investorshub | 04/25/2022 2:27:17 PM |
Data @ CC > 8:00AM EST | crudeoil24 | investorshub | 04/25/2022 11:36:17 AM |
Link to webcast https://www.veracast.com/webcasts/clients/webcasts/KdH3SE.cfm | jondoeuk | investorshub | 04/23/2022 4:45:35 PM |
The company will host a conference call on | jondoeuk | investorshub | 04/23/2022 4:41:09 PM |
AACR PR https://www.globenewswire.com/news-release/2022/04/08/2419482/0/en/Nkart | jondoeuk | investorshub | 04/09/2022 8:29:20 PM |
NKX101 (R/R AML and higher-risk MDS): Dose escalation | jondoeuk | investorshub | 04/03/2022 11:11:48 PM |
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis IND cleared for Ntrust-2, a clinical trial for NKX019 for the treatment of systemic sclerosis, myositis and vasculitis Clinical data ...